Tirofiban versus abciximab: Tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates

Clinical and Experimental Medicine

Volumn 12, Issue 4, 2012, Pages 257-263

  Van Rensburg, Walter J Janse ^a   Roodt, Jan P ^a,b   Lamprecht, Seb ^a   Meiring, S Muriel ^a,b   Badenhorst, Philip N ^a  

^a UNIVERSITY OF THE FREE STATE   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

Abciximab; Acute coronary syndrome; Arterial thrombosis animal model; Glycoprotein IIb IIIa inhibitors; Tirofiban

Indexed keywords

ABCIXIMAB; TIROFIBAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; BABOON; BLEEDING; BLEEDING TIME; BLOOD CELL COUNT; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RECOMMENDED DRUG DOSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN FAB FRAGMENTS; PRIMATES; THROMBOSIS; TREATMENT OUTCOME; TYROSINE;

ANIMALIA; PRIMATES;

EID: 84870441911     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-011-0171-4     Document Type: Article

References (32)

1. Achar SA, Kundu S, Norcross WA (2005) Diagnosis of acute coronary syndrome. Am Fam Physician 72:119-126 (Pubitemid 40965544)
2. Grech ED, Ramsdale DR (2003) Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. BMJ 326:1259-1261 (Pubitemid 36688090)
3. Falk E (2006) Pathogenesis of atherosclerosis. J Am Coll Cardiol 47(Suppl 8):C7-C12
4. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction -executive summary. J Am Coll Cardiol 50:652-726
5. EPIC Investigators (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 330:956-961
6. EPILOG Investigators (1997) Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336:1689-1696
7. CAPTURE Investigators (1997) Randomised placebo-controlled trial of abciximab before, during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 349: 1429-1435
8. IMPACT-II Investigators (1997) Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to minimise platelet aggregation and coronary thrombosis-II. Lancet 349:1422-1428
9. The RESTORE Investigators (1997) Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized efficacy study of tirofiban for outcomes and restenosis. Circulation 96:1445-1453
10. EPISTENT Investigators (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 352:87-92
11. ESPRIT Investigators (2000) Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356:2037-2044
12. Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P et al (2002) Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison of measurements of platelet aggregation with Aggrastat, Reopro, and eptifibatide. Circulation 106:1470-1476
13. Herrmann HC, Swierkosz TA, Kapoor S, Tardiff DC, DiBattiste PM, Hirshfeld JW et al (2002) Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q wave myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 89:1293-1297 (Pubitemid 34606892)
14. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ et al (2001) Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 334:1888-1894 (Pubitemid 32553357)
15. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Wan Y, Aggarwal A et al (2002) Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol 90:1421-1423 (Pubitemid 35449499)
16. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Lo M, Yin K et al (2003) Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol 91:334-336 (Pubitemid 36143875)
17. Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S et al (2008) Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimuseluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 299:1788-1799 (Pubitemid 351549970)
18. Marzocchi A, Manari A, Piovaccari G, Marrozzini C, Marra S, Magnavacchi P et al (2008) Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial. Eur Heart J 29:2972-2980
19. Valgimigli M, Biondi-Zoccai G, Tebaldi M, Van't Hof AWJ, Campo G, Hamm C et al (2010) Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trial. Eur Heart J 31:35-49
20. Fontayne A, Meiring M, Lamprecht S, Roodt J, Demarsin E, Barbeaux P et al (2008) The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear rate arterial thrombosis model in baboons. Thromb Haemost 100:670-677
21. Ulrichts H, Silence K, Schoolmeester A, De Jaegere P, Rossenu S, Roodt J et al (2011) Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared to currently marketed antiplatelet drugs. Blood Prepublished online 16 May, 2011. doi:10.1182/blood-2010-11-317859
22. Kralisz P, Dobrzycki S, Nowak K, Kochman W, Gajewska-Bacho'rzewska H, Gugala K et al (2004) Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction. Kardiologia Polska 60: 464-467
23. Lind SE (1991) The bleeding time does not predict surgical bleeding. Blood 77:2547-2552
24. Peterson P, Hayes TE, Arkin CF, Bovill EG, Fairweather RB, Rock WA Jr et al (1998) The preoperative bleeding time test lacks clinical benefit. Arch Surg 133:134-139
25. Benedict CR, Ryan J, Wolitzky B, Ramos R, Gerlach M, Tijburg P et al (1991) Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest 88:1760-1765
26. Thiagarajan P, Benedict CR (1997) Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model. Circulation 96:2339-2347 (Pubitemid 27425842)
27. Fenton DE (2009) Acute coronary syndrome. (eMedicine online). Updated August 6, 2009. Available at http://emedicine.medscape. com/article/756979- overview. Accessed 8 Feb 2010
28. Falk E, Shah PK, Fuster V (1995) Coronary plaque disruption. Circulation 92:657-671
29. Lynch JJ Jr, Cook JJ, Sitko GR, Holahan MA, Ramjit DR, Mellott MJ et al (1995) Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383. J Pharmacol Exp Ther 272:20-32
30. Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T et al (1996) Randomized, double-blind, placebocontrolled dose-ranging study of tirofiban (MK-383) platelet IIb/ IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 27:536-542 (Pubitemid 26081915)
31. Moliterno DJ, Topol EJ (2002) The TARGET trial: hit or miss? Eur Heart J 23:835-837 (Pubitemid 34717415)
32. Soffer D, Moussa I, Karatepe M, Harjai KJ, Boura J, Dixon SR et al (2003) Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris. Am J Cardiol 91:872-875 (Pubitemid 36363736)